Drugs / RPI.4610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00021021 | Sep 2001 → Feb 2004 | kidney cancer | Ribozyome | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPI.4610 | “PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patients who have metastatic kidney cancer.” NCT00021021 ↗ |
| Action | Inhibit | “anti-FLT-1 ribozyme” NCT00021021 ↗ |
| Modality | Oligonucleotide (other) | “anti-FLT-1 ribozyme” NCT00021021 ↗ |
| Route | Subcutaneous | “Patients receive RPI.4610 subcutaneously daily.” NCT00021021 ↗ |
| Target | FLT1 | “anti-FLT-1 ribozyme” NCT00021021 ↗ |